Toggle Main Menu Toggle Search

ePrints

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival

Lookup NU author(s): Dr Simon Bomken, Dr Barry Davies, Mike Cole, Dr Katrina Wood, Maritsa McDermott, Professor Deborah Tweddle

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The percentage of chemotherapy-induced necrosis in primary tumors corresponds with outcome in several childhood malignancies, including high-risk metastatic diseases. In this retrospective pilot study, the authors assessed the importance of postchemotherapy necrosis in high-risk neuroblastoma with a histological and case notes review of surgically resected specimens. The authors reviewed all available histology of 31 high-risk neuroblastoma cases treated with COJEC (dose intensive etoposide and vincristine with either cyclophosphamide, cisplatin or carboplatin) or OPEC/OJEC (etoposide, vincristine and cyclosphosphamide with alternating cisplatin [OPEC] or carboplatin [OJEC]) induction chemotherapy in 2 Children's Cancer & Leukaemia Group (CCLG) pediatric oncology centers. The percentage of postchemotherapy necrosis was assessed and compared with MYCN amplification status and overall survival. The median percentage of postchemotherapy tumor necrosis was 60%. MYCN status was available for 28 cases, of which 12 were amplified (43%). Survival in cases with ≥60% necrosis or ≥90% necrosis was not better than those with less necrosis, nor was percentage necrosis associated with survival using Cox regression. However, MYCN-amplified tumors showed a higher percentage of necrosis than non–MYCN-amplified tumors, 71.3% versus 37.2% (P = .006). This effect was not related to prechemotherapy necrosis and did not confer improved overall survival. Postchemotherapy tumor necrosis is higher in patients with MYCN amplification. In this study, postchemotherapy necrosis did not correlate with overall survival and should not lead to modification of postoperative treatment. However, these findings need to be confirmed in a larger prospective study of children with high-risk neuroblastoma.


Publication metadata

Author(s): Bomken S, Davies B, Chong L, Cole M, Wood KM, McDermott M, Tweddle DA

Publication type: Article

Journal: Pediatric Hematology & Oncology

Year: 2011

Volume: 28

Issue: 2

Pages: 106-114

Print publication date: 08/01/2011

ISSN (print): 0888-0018

ISSN (electronic): 1521-0669

Publisher: Informa Healthcare

URL: http://dx.doi.org/10.3109/08880018.2010.526684

DOI: 10.3109/08880018.2010.526684


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share